A promising class of therapeutics for the treatment of MASH are GLP-1 receptor agonists (GLP-1RAs)47, which have also transformed the treatment landscape for people living with T2D and obesity based on their ability to regulate glucose and cause weight loss through reduced caloric intake, respectively22,48. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.